Interruption of marketing · 03.09.2026
Supply shortage Czechia: NIMOTOP S 30MG TBL FLM 100 III
Affected country: Czechia · Reported period: 31.08.2026 – 31.05.2027 · Active ingredient: NIMODIPIN
Notice context
A supply shortage has been recorded for NIMOTOP S 30MG TBL FLM 100 III in Czechia. The stated reason is “Procedural/regulatory reasons”. The notice concerns the active ingredient NIMODIPIN and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Czechia. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for NIMOTOP S 30MG TBL FLM 100 III is a supply signal concerning NIMODIPIN in Czechia. The published reason “Procedural/regulatory reasons” determines which data should be verified first.
For market or regulatory restrictions, authorisation and distribution status, pack version, destination country and the lawful sourcing route require separate assessment.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess product, authorisation, distribution and recipient status and the lawful case-specific sourcing route.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For market or status changes, the lawful product, distribution and recipient status for NIMOTOP S 30MG TBL FLM 100 III must be clarified before storage.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using record SÚKL-Code 0280362; Meldungs-ID 94575, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 31.08.2026 to 31.05.2027 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving NIMOTOP S 30MG TBL FLM 100 III: